About Us
As a global leader in rapid testing, Abbott’s point-of-care testing technology provides actionable results in minutes for clinicians to determine the most appropriate care pathway. Abbott’s product portfolio spans key diagnostic testing areas such as infectious disease, cardiovascular disease, diabetes and connectivity solutions.
Our Response To Escalating Challenges
The world’s healthcare systems were already overburdened by the growing impacts of aging populations and chronic disease — and that was before COVID-19. Access to care is limited. Cost is always a concern and health gaps are widening across society.
A third of people today lack access to essential health products and technologies.
There’s an 18-year difference in life expectancy between rich and poor countries.
Global annual healthcare spending is projected to reach $16 trillion in 2029.
Humanity will need nearly 20 million additional health workers over the next 10 years.
Those are big numbers. They demand a big response. This is ours.
Advance health equity through partnership
We work side-by-side with people, the communities we serve, partners, and governments to address health disparities. Expanding access and removing barriers that prevent people from living healthy lives, wherever they are.
- We are expanding affordable access to healthcare for underserved, diverse, and at-risk communities, including women and children.
- We are delivering innovative, decentralized models of care that advance prevention and early diagnosis, improve nutrition, provide quality treatment and care, and lower total costs.
- We partner with stakeholders to improve health outcomes by advancing standards and building access to affordable, integrated solutions.
Our Products
ID NOW™
A platform for detection of Flu A & B, Strep A, RSV, and COVID-19 infections, providing the fastest rapid molecular results within 2 to 13 minutes 1
Determine™ HIV-1/2 Ag/Ab Combo
First and only FDA approved 4th generation rapid test, detecting both acute and chronic HIV infection with results in 20 minutes
Afinion™ 2
Compact, rapid analyzer that provides fast and reliable HbA1c and ACR test results in as little as 3 to 5 minutes at the point-of-care
Cholestech LDX™ Analyzer
Rapid, accurate results in 5 minutes for a complete lipid profile and glucose to identify CVD risks
BinaxNOW™ COVID Ag Card
Designed to detect active COVID-19 infections with or without symptoms (authorized under EUA)*
iCassette Urine Test Dx Fentanyl Drug Screen
Help keep your community safe with a CLIA waived point-of-care urine test cassette for detection of Fentanyl with 1ng/mL cutoff
Our Promotion
Choose which of the above products will best serve your community
Select the option that is right for you
Capital Option
– No Contracts
– No volume commitments required
Placement Option
– Aggregate annual spend commitment
– One agreement for all products **
– No upfront instrument capital needed
Contact us below to learn how Abbott can help make an impact in your community
Want to learn more
our team is here to help
* The BinaxNOW™ COVID-19 Ag Card has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner
** Clinical Toxicology products covered under separate agreement